Results 51 to 60 of about 33,583 (261)
Mediators of Inflammation, 2017 Interleukin-1β (IL-1β) is a pleiotropic cytokine and a crucial mediator of inflammatory and immune responses. IL-1β processing and release are tightly controlled by complex pathways such as NF-kB/ERK1/2, to produce pro-IL-1β, and NALP3/ASC/Caspase-1 ...
Letizia Mezzasoma +2 more
doaj +1 more source
Galician Medical Journal, 2016 In the development of essential hypertension cardiac remodeling is determined by both hemodynamic and neurohumoral factors. The influence of hemodynamic factors is sufficiently studied, while the role of stimulating and inhibiting humoral agents in the ...
Іuliia P Pashkova
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi +4 more
wiley +1 more source
Journal of Lipid Research, 2001 We recently demonstrated that natriuretic peptides and especially the atrial natriuretic peptide (ANP) are powerful lipolytic agents on isolated human fat cells.
Jean Galitzky +6 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori +5 more
wiley +1 more source
Cardio-Oncology, 2023 Background Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or precluding chemotherapy entirely ...
Ali Mir +11 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1464-1468, April 2025.Abstract Background There are limited data on the efficacy of smartphone‐based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD). Methods This
Kotaro Nochioka +16 more
wiley +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
Molecules, 2020 Cardiac hypertrophy is a major risk factor for heart failure and leads to cardiovascular morbidity and mortality. Doxorubicin (DOX) is regarded as one of the most potent anthracycline antibiotic agents; however, its clinical usage has some limitations ...
Jung Joo Yoon +6 more
doaj +1 more source